NRx Pharmaceuticals, Inc. NRXP
3.00
(0.03)
(0.99%)
as of 25 Sep
- Market cap
- $131.2M
- P/E
- 0.0×
Follow NRXP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
45.37 | 0.00 | 0.00 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(17.35) | (16.03) | (15.62) | (25.38) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
39.10 | 0.00 | 0.00 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.71) | (5.17) | (4.63) | (6.50) | |
EV/FCF |
(6.42) | (5.17) | (4.62) | (6.50) | |
Quick Ratio |
0.79 | 0.27 | 0.28 | 0.26 | |
Current Ratio |
0.86 | 0.29 | 0.31 | 0.29 | |
Net Debt/EBITDA |
4.15 | 1.47 | 1.72 | (0.71) | |
Debt/Assets |
1.21% | 0.00% | 0.00% | 67.09% | |
Debt/Equity |
(2.42) | 0.00 | 0.00 | (0.39) | |
Asset Turnover |
0.17 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.54 | 3.00 | (10.29) | 0.49 | |
Capex/Depreciation |
(5.18) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
192.19% | 122.57% | 56.66% | 590.50% | |
Selling, General and Administrative Expense of Revenue |
430.97% | 357.02% | 464.60% | 1,160.33% | |
Intangible Assets out of Total Assets |
0.08 | 0.22 | 0.21 | 0.16 | |
Share Based Compensation of Revenue |
12.62% | 14.14% | 8.24% | 28.10% | |
Graham Net Nets |
(0.03) | (0.27) | (0.34) | (0.39) | |
Graham Number |
0.24 | 3.24 | 4.83 | 7.83 | |
Earnings Yield |
(13.45%) | (51.17%) | (51.29%) | (71.21%) | |
Free Cash Flow Yield |
(13.42%) | (21.68%) | (24.34%) | (17.04%) | |
Revenue per Share |
0.03 | 0.03 | 0.05 | 0.01 | |
Operating CF per Share |
(0.24) | (0.13) | (0.17) | (0.13) | |
Capex per Share |
(0.02) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.26) | (0.13) | (0.17) | (0.13) | |
Cash per Share |
0.71 | 0.21 | 0.36 | 0.32 | |
Shareholders Equity per Share |
0.00 | (0.43) | (0.74) | (1.16) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | (0.43) | (0.74) | (1.16) | |
Free Cash Flow |
(9.77) | (4.29) | (3.71) | (2.89) | |
Working Capital |
(4.72) | (17.81) | (19.69) | (28.65) | |
Capital Expenditures |
(0.90) | — | — | — | |
Net Current Asset Value |
(5.17) | (18.36) | (20.00) | (28.80) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.81 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(1,500.45%) | (133.90%) | 36.72% | (2,433.88%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.11 | 0.09 | 0.08 | 1.94 | |
Average Payables |
3.39 | 4.36 | 4.20 | 4.56 | |
Average Assets |
19.50 | 9.75 | 8.30 | 9.73 | |
Average Common Equity |
(17.89) | (19.49) | (19.58) | (22.29) |
Columns are period end dates